UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma

BMC cancer, 2022-07, Vol.22 (1), p.720-720, Article 720

2022

Volltextzugriff (PDF)

Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer

Journal of clinical oncology, 2012-10, Vol.30 (28), p.3552-3557

2012

Volltextzugriff (PDF)

Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review

Cancer treatment reviews, 2020-07, Vol.87, p.102032-102032, Article 102032

2020

Volltextzugriff (PDF)

Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors

Melanoma research, 2021-06, Vol.31 (3), p.258

2021

Volltextzugriff (PDF)

Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review

Surgical oncology, 2024-06, Vol.54, p.102077, Article 102077

2024

Volltextzugriff (PDF)

Characteristics and outcomes of patients (pts) who developed immune-related adverse events (irAEs) with an initial presentation in the emergency department (ED)

Journal of clinical oncology, 2020-10, Vol.38 (29_suppl), p.201-201

2020

Volltextzugriff (PDF)

Long-term toxicities with immune checkpoint inhibitor (ICI) in melanoma patients

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21549-e21549

2022

Volltextzugriff (PDF)

Non-classical BRAF melanoma: A retrospective review of disease characteristics and prognostic implications

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e21060-e21060

2017

Volltextzugriff (PDF)

Can high-dose methotrexate be safely administered to outpatients?

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.34-34

2021

Volltextzugriff (PDF)

Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9552-9552

2021

Volltextzugriff (PDF)

Using information technology (IT) to improve communication between the emergency room and cancer clinic

Journal of clinical oncology, 2016-03, Vol.34 (7_suppl), p.158-158

2016

Volltextzugriff (PDF)

Immunotherapy efficacy and toxicity in a real-world elderly population

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e15137-e15137

2018

Volltextzugriff (PDF)

A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS8074-TPS8074

2020

Volltextzugriff (PDF)

Developing a standard approach to immune checkpoint inhibitor toxicity management in Ontario

Journal of clinical oncology, 2018-10, Vol.36 (30_suppl), p.255-255

2018

Volltextzugriff (PDF)

A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS9600-TPS9600

2018

Volltextzugriff (PDF)

Toxicity of high-dose interferon for high-risk melanoma in Ontario: A population-based study of health services use

Journal of clinical oncology, 2017-03, Vol.35 (8_suppl), p.31-31

2017

Volltextzugriff (PDF)

Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome

Canadian journal of cardiology, 2009-06, Vol.25 (6), p.e210-e212

2009

Volltextzugriff (PDF)

Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma

Human pathology, 2011-07, Vol.42 (7), p.972-982

2011

Volltextzugriff (PDF)

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3467-3474

2015

Volltextzugriff (PDF)

Identification of genetic subtypes in follicular lymphoma

Blood cancer journal (New York), 2024-08, Vol.14 (1), p.128-13, Article 128

2024

Volltextzugriff (PDF)

MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2903-2911

2013

Volltextzugriff (PDF)

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Blood, 2019-11, Vol.134 (Supplement_1), p.768-768

2019

Volltextzugriff (PDF)

Differential Expression of TCF3 Target Genes Defines Subclasses of Diffuse Large B-Cell Lymphoma with Striking Differences in Clinical Outcome Following R-CHOP Therapy

Blood, 2016-12, Vol.128 (22), p.3037-3037

2016

Volltextzugriff (PDF)

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A Phase II study by the national cancer Institute of Canada Clinical Trials group (NCIC-CTG)

Cancer, 2004-10, Vol.101 (8), p.1835-1842

2004

Volltextzugriff (PDF)

Phase II study of perifosine in previously untreated patients with metastatic melanoma

Investigational new drugs, 2005-12, Vol.23 (6), p.569-575

2005

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(12)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Oncology
(10)
Female
(6)
Male
(6)
Middle Aged
(6)
Adult
(5)
Aged
(5)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Tumors
(5)
Aged, 80 And Over
(4)
Hematologic And Hematopoietic Diseases
(4)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(4)
Melanoma
(4)
Prognosis
(4)
Melanoma - Drug Therapy
(3)
Melanoma - Pathology
(3)
Melanoma, Cutaneous Malignant
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma

Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer

Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review

Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors

Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review

Characteristics and outcomes of patients (pts) who developed immune-related adverse events (irAEs) with an initial presentation in the emergency department (ED)

Long-term toxicities with immune checkpoint inhibitor (ICI) in melanoma patients

Non-classical BRAF melanoma: A retrospective review of disease characteristics and prognostic implications

Can high-dose methotrexate be safely administered to outpatients?

Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma

Using information technology (IT) to improve communication between the emergency room and cancer clinic

Immunotherapy efficacy and toxicity in a real-world elderly population

A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma

Developing a standard approach to immune checkpoint inhibitor toxicity management in Ontario

A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13

Toxicity of high-dose interferon for high-risk melanoma in Ontario: A population-based study of health services use

Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome

Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

Identification of genetic subtypes in follicular lymphoma

MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Differential Expression of TCF3 Target Genes Defines Subclasses of Diffuse Large B-Cell Lymphoma with Striking Differences in Clinical Outcome Following R-CHOP Therapy

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A Phase II study by the national cancer Institute of Canada Clinical Trials group (NCIC-CTG)

Phase II study of perifosine in previously untreated patients with metastatic melanoma

Suchergebnisse filtern